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                  Into the Valley of Death: Research to Innovation 
Abstract  
The pharma industry and academia are increasingly working together, often encouraged by 
governments, as they seek to bring basic research to the market. This is consistent with newer 
models of innovation policy which stress interaction between the different agents across the 
innovation process. We examine this interaction in the UK, the EU and the US in part 
through several specific examples. They suggest that co-operation is still far from perfect and 
that academia’s return on its research is relatively small. Countries are also beginning to use 
research as a tool of industrial economic policy. 
 
The phase between research and successful innovation is known as the Valley of Death. The 
pharma industry and academia are increasingly working together, often encouraged by 
governments, as they seek to successfully navigate the Valley and bring research to the 
market. This is consistent with newer models of innovation policy which stress interaction 
between the different agents across the innovation process. We examine this interaction, in 
part through several academic research case studies. They suggest that co-operation has been 
focused on the research stages of innovation and that academia’s return on its IPR is 
relatively small. Countries are also beginning to use research as a tool of industrial economic 
policy. 
 
The nature of innovation 
Until the 1990s the linear model of innovation policy was dominant. This viewed technical 
change as happening in a linear fashion from invention to innovation to diffusion. The stages 
of the "Technology Push", version of the original linear model, are: Basic science→Design 
and engineering→ Manufacturing→ Marketing→ Sales. In this model the role of universities 
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is often fundamental. However, in the past decade a new understanding of the nature of the 
innovation process has emerged, which emphasizes its systemic and interactive character [1]. 
This suggests that innovation should be seen as an evolutionary, non-linear and interactive 
process, requiring intensive communication and collaboration between firms and 
organisations such as universities, financial institutions and government agencies. An 
example of this is the triple helix model which emphasises interaction between university, 
industry and government [2] and a more system-centred approach to innovation policy [3]. 
This does not mean that focusing on basic research and on the technological aspects of 
innovation is the wrong policy, but that it needs to be complemented with the organisational, 
financial, skill and commercial aspects of innovation.  
    In tune with this, the OECD [4] argue that much innovation appears to fail because of a 
lack of co-ordination and a failure to join up all the agents who are part of the innovation 
process. Finance is often a key constraining factor. Innovation in the pharma industry, where 
an aspect of the Valley of Death is the translation gap, is particularly fraught with problems. 
Translation may be defined as the transfer of basic biomedical research into clinical 
interventions. It correlates with the design and engineering stage of the linear model and the 
problems are substantial. The time-lag between filing a basic patent on a compound and its 
commercialization as a drug is long at about 11–12 years and only a small fraction of all 
synthesized compounds finally enter the market [5]. The average cost of taking a drug from 
concept to market is estimated to be in excess of $1 billion and only 20% of approved drugs 
make more money than their associated R&D cost [6]. Even then, dangerous side effects may 
emerge for some drugs after several years of sales. This has led to increasingly stringent 
regulatory approval guidelines, making an already slow system [7] even slower. Further 
obstacles to translation are discussed in [8]. All of this often makes funding difficult to 
obtain, particularly for the early stages of translation research. 
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The changing roles of firms, universities and governments in the pharmaceutical 
industry 
Translation research can be done either by large pharmaceutical firms, specialist SMEs or 
universities, often via spin-out companies. In recent years the latter have become increasingly 
common [9]. Moving away from the linear model, there has also been an increasing tendency 
for industry, encouraged by government as in the triple helix, to finance and engage with 
academia at an early stage of research, often in the form of research centres [6]. In part 
universities welcome such engagement because of increased financial pressures. Traditionally 
the pharmaceutical industry preferred to keep research in-house [9]. But arguably in the face 
of rising costs and greater difficulties in finding major new drugs, they too welcome greater 
collaboration with universities [7]. 
 
Examples from the UK and the USA 
 
Examples from the Medical Research Council 
The UK’s Medical Research Council (MRC) in its annual reports and associated documents 
details the economic impact of research it has part-funded. Superficially it tells a good story. 
Perhaps the stand out item is the receipt of over $200m from the drug Humira, an anti-TNF 
antibody therapy, used to treat arthritis. This uses patented technology derived from research 
at the MRC Laboratory of Molecular Biology in Cambridge and the Scripps Research 
Institute in California. By August 2009 it was being used in 80 countries in the treatment of 
370,000 patients, and estimated to be the world’s top-earning pharmaceutical product with 
projected sales of $10billion by 2016 for the US firm Abbott Laboratories. Indeed in April 
2012 its sales in the previous year were reported as $2.3billion. Overall, in the period 2006-
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10 the MRC reported that 315 unique patents were granted or published and 99 patents had 
been licensed. IPR (intellectual property rights) income was £78.9m in 2011/2012 and MRC 
funding has also contributed to the establishment of 47 start up firms since 2006.  
 
Examples from the Research Excellence Framework impact case studies 
These bare bones of the impact of research funding are given more flesh by a series of case 
studies which can be found on the UK’s Higher Education Funding Council for England’s 
website. These were the outcome of a pilot exercise designed to inform the Research 
Excellence Frame work (REF), which is the latest attempt by the UK government to evaluate 
academic research. A key difference to its predecessors is a greater emphasis on the 
economic and societal impact of research.  
    The case studies from Clinical Medicine (details of which can be found on 
http://www.ref.ac.uk/media/ref/content/background/impact/ClinicalMedicine.pdf) include 
Imperial College’s Thiakis, a spin-out company which has been sold twice, ending up with 
Pfizer. The underlying research pioneered the use of gut hormones as natural appetite 
regulators. This paved the way for the use of this hormone, related analogues and inhibitors 
of GLP-1 breakdown in the treatment of diabetes. Several GLP-1 related molecules (e.g. 
exanatide, liraglutide, vildagliptin) are now either licensed or undergoing clinical trials (e.g. 
Byetta, NovoNordisk). Further studies demonstrated that i.v. infusion of oxyntomodulin 
reduces food intake and thus facilitates weight loss. One particular analogue was developed 
by Thiakis, and was then evaluated by Pfizer as a potential therapy for obesity. However, 
there are reports that in 2012 Pfizer has ceased to develop this, with its future now uncertain 
(http://www.bioworld.com/content/imperial-innovations-regaining-thiakis-obesity-drug-
pfizer). This is representative of the risks to firms of taking on university research, and indeed 
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vice versa. But it also illustrates the containment of that risk, as part of the payment to 
Imperial was dependent upon critical milestones being achieved. 
    The second Imperial College case study involving the treatment for rheumatoid arthritis 
(RA), does not seem to have directly financially benefitted Imperial from IPR revenues, but 
amongst the funders of this research are listed GSK and Wyeth, mainly for specific 
translational research. The case study is linked to the anti-TNF (tumor necrosis factor) drugs 
of which Humira is one. The research demonstrated that biologic TNF inhibition plus 
methotrexate markedly inhibits the structural joint damage previously thought to be an 
irreversible feature of RA and has led to the use of monoclonal antibodies to TNF for other 
chronic diseases, such as ankylosing spondylitis and Crohn's disease. 
 
Other case studies 
The other case studies do not relate to the development of new drugs per se, but there are still 
benefits to the universities and the UK, and they illustrate the diverse aims behind the public 
funding of university research. Cardiff’s research has facilitated the identification and 
characterisation of a series of genes for major inherited disorders including autosomal 
recessive colorectal cancer and Huntington’s disease. New genetic tests, developed in 
Cardiff, which allow earlier and more accurate diagnosis, are now available in the UK and 
Europe. In North America, Myriad Genetics markets the Colaris AP® testing kit which uses 
Cardiff’s MYH gene technology, generating over £100,000 in royalty income for Cardiff 
University. However, this is not such a large amount compared to Myriad’s revenue from the 
Colaris AP test, which together with the Colaris test, amounted to $43.3 million in the fiscal 
year 2012.  
    At Exeter and Plymouth, research showed that the most common cause of permanent 
neonatal diabetes was a mutation(s) residing in a region encoding the pore-forming subunit of 
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a type of potassium channel which senses and responds to alterations in the ratio of 
ATP:ADP in the beta-cells. Research at Oxford showed that the early risk of a major stroke 
in the first few days after more minor 'warning' events, was much higher than had previously 
been supposed and developed simple clinical risk scores to identify high-risk patients. 
Finally, at Glasgow a study researched the evidence that smoke-free legislation has a 
significant impact on heart disease.  
 
The Situation in the USA 
For several decades Government policies have been designed to help commercially develop 
federally supported R&D. These include financial support and encouragement for the 
establishment of Technology Licensing Organizations and intellectual property centres as 
well as legislative changes such as the Bayh-Dole Act of 1980. The latest legislative change, 
the Leahy-Smith America Invents Act (AIA) of 2011, takes effect in 2013. A key aspect is 
the move from "first-to-invent" to "first-to-file", by which in the event of multiple patent 
application files, priority will be given to the one filed first. There are several other aspects to 
this legislation and it has been described as the biggest change to the US patent system since 
the 1950s. It has in part been designed to reduce legal challenges to patents, but also brings 
the US system closer to that of other countries. In doing so it may give an inducement for 
patents to be files earlier, and this may encourage universities to collaborate with the private 
sector at an earlier stage.  
    The NIH in their annual reports seem keen to emphasise that their spending benefits every 
state and almost every congressional district, rather than the specific impact of spending in 
generating new products with a stream of license income. They also stress the benefits to 
health and in general terms that their research has helped keep the US pharma industry in a 
strong position globally. With respect to individual universities, in the Association of 
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University Technology Managers (AUTM) survey (see http://www.autm.net/Home.htm) of 
157 colleges and universities in 2011 licensed income amounted to over $1.8 billion. For 
most this was still a small proportion of research expenditures, on average just 2.2%. 
Northwestern University was the largest earner and their $192 million was 40% of their total 
research expenditure. Amongst their outputs is Pfizer’s Lyrica, sales of which were $3.693 
billion according to their 2011 Annual Accounts.   
 
An evolving research environment 
Ideally the new view of research would suggest that the company marketing the drug will 
already have been identified and indeed involved in the research right at its outset. However 
in the traditional university funding model, as illustrated in many of the case studies, this 
does not happen. To a considerable extent research funders in many countries are operating 
within the context of a linear innovation model. Requests for funding are received and are 
evaluated largely on the basis of their ‘scientific merit’, although economic impact is, 
superficially at least, beginning to be taken into account. In many cases, only once the 
research is close to completion does serious thought appear to be given to successfully 
bringing the innovation to market.  
    But an alternative scenario, more consistent with newer models of research, is beginning to 
emerge which sees industry, academia, research funders and even central government, co-
operating at the start of a research project. Thus in 2012 Bristol-Myers Squibb announced a 
collaboration with ten cancer research institutions in Europe and the USA, with the specific 
aim of facilitating translation research. Whilst GSK and Astra have collaborated with the 
University of Manchester in  translating basic research into new medicines for inflammatory 
diseases. GSK has several other partnership deals including ones with UCL, Cambridge and 
Nottingham Universities in the UK and Yale in the USA. In America Harvard joined forces 
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with Evotec, a German based biotech firm, with a further link to Janssen Pharmaceuticals set 
up in 2012. This saw an upfront payment of $8 million split between the two original partners 
and gives Janssen exclusive access to a portfolio of products designed to trigger the 
regeneration of insulin-producing cells. There is also specific support for translational 
research by the EU’s Innovative Medicines Initiative (IMI) and the MRC’s Developmental 
Pathway Funding Scheme Such developments are bringing academics much closer to the 
private sector in their daily working life. To an extent academia is becoming the de facto 
research arm of the pharma industry. 
    In Europe too, increasingly there are examples of university centres sponsored by, and 
identified with, the large multinationals, e.g. the Mitsubishi Genetic Therapies Centre at 
Imperial College. The French government have funded an initiative to create six world poles 
of excellence bringing together French firms and publicly funded research centres in a bid to 
keep France in the forefront of pharmaceutical innovation and production [7]. The IMI also 
supports collaborative research projects and builds networks of industrial and academic 
experts in Europe. In America, the NIH’s Roadmap Initiative also makes some developments 
in this direction (see http://commonfund.nih.gov/aboutroadmap.aspx), with the specific aim 
of changing the academic culture to foster collaboration.  
 
Concluding remarks 
The process of bringing basic research to successful innovation is changing with closer 
collaboration between industry, academia and government agencies. At the same time in 
some cases universities are themselves taking new drugs further down the innovation chain 
through spin-out companies. All these developments should facilitate the more efficient 
development of new drugs. They may also help with the provision of venture capital and 
other funding for translational research in general, and early translational research in 
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particular, which tends to be in short supply. This may then help researchers, universities and 
government meet their moral, and financial, obligation to translate basic research to clinical 
validation and benefit. 
    In addition it is possible that they will lead to universities and industry sharing more 
equally in the gains from research. The evidence suggests that the income generated from  
IPR is relatively small compared to the total revenues being generated and the total costs of 
research. Hence average license income in Europe equals 1.5% of the research expenditures 
by universities and research institutes and in the US it is 4% (see http://www.knowledge-
transfer-study.eu). Of course, not all research is intended to directly generate revenue, but the 
examples we gave earlier suggest that universities and their funders are selling their IPR too 
cheaply. The work behind some of these case studies has taken over 30 years, mainly funded 
minimally by research grants and the universities have failed to be effectively compensated 
when these are successfully commercialised.  
    However, it is not obviously the case that this integrated approach to university research 
involving multiple partners will improve the universities’ position in this respect. Firstly, 
even the largest universities do not have the financial and legal expertise to bargain with the 
pharmaceutical industry (big pharma) on an equal footing, or to efficiently move further 
down the translational path themselves. This will require a collective pooling of resources 
and skills. Secondly, a patent is only valuable as a protection of property if the holder is 
prepared to sue intruders, if not the value of the patent is undermined. Yet universities may be 
reluctant to do this for a variety of reasons including the direct costs, and the impact on image 
and job prospects for graduates. Finally, not all collaborations end in success as illustrated in 
the case studies and the literature survey. The closeness of the relationship between the 
different partners and the alignment of their diverse goals may well prove important in 
facilitating such success.   
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    There are also ethical problems involved with this new approach. Firstly it clashes with 
academia’s traditional focus on disseminating knowledge as widely and freely as possible, 
and risks taking the focus away from high quality research publications [10]. Possibly in an 
attempt to protect themselves from criticism, some universities are seeking to ensure that 
products from their IPR are marketed under favorable conditions to the developing world. 
These include Boston, British Colombia, Brown, Edinburgh, Emory, Oxford, Washington, 
Yale and UCL. Secondly, it involves, directly or indirectly, public money underwriting the 
commercial success of some firms and not others.  
    This use of public money is being done not just to promote research per se, but 
increasingly as a tool of industrial and economic policy, as in France, with their poles of 
excellence, Germany and more widely the EU. Even in the US, where there has been a 
traditionally reliance on market forces, the NIH is beginning to view research as a way of 
boosting the economy and has long, implicitly sought to strengthen the global position of 
American companies. However it is also often the case, as in the UK, that the firms 
benefitting from the research are foreign based multinationals and hence the boost is to other 
economies. In this context, certainly within the UK, greater domestic support for candidate 
translation is required to help avoid migration to other countries with greater funding. 
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